Navidea's Macrophage heralds preclinical drug conjugate for Kaposi's sarcoma; Biogen links up with AGTC on blindness gene therapy;

> Macrophage Therapeutics, part of Navidea ($NAVB), announced preclinical results from its study of doxorubicin linked to its drug conjugate Manocept as a treatment for Kaposi's sarcoma. Release

> Biogen ($BIIB) and AGTC have joined forces to develop gene therapies for ophthalmologic use. AGTC's main foci are diseases of the retina that can lead to blindness. Release

BD&L Summit

Deal-Making Insights for the Life Sciences Industry

Bringing together key deal-makers and serving as an open forum for cross-functional business development and legal teams to share valuable insights and actionable strategies on successfully managing alliances, licensing agreements, and M&A deals.